DoH Policies screened during the period: 1 April 2016 to 30 June 2016
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE (Public Health) Guideline – PH56 - Vitamin D: increasing supplement use among at-risk groups
- NICE (Clinical) Guideline NG41 – Spinal injury: assessment and initial management
- NICE (Clinical) Guideline NG40 – Major trauma: service delivery
- NICE (Clinical) Guideline NG39 - Major trauma: assessment and initial management
- NICE (Clinical) Guideline NG 38 - Fractures (non-complex): assessment and management
- NICE (Clinical) Guideline NG 37 - Fractures (complex): assessment and management
- NICE Technology Appraisal TA20 - Riluzole (Rilutek) for the treatment of Motor Neurone Disease
- NICE (Clinical) Guideline NG42 - Motor neurone disease: assessment and management
- NICE (Public Health) Guideline – NG44 - Community engagement: improving health and wellbeing and reducing health inequalities
- NICE Guideline NG35 - Myeloma: diagnosis and management
- NICE (Clinical) Guideline CG72 – Attention deficit hyperactivity disorder: diagnosis and management – Addendum
- NICE (Clinical) Guideline NG36 – Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over
- NICE (Public Health) Guideline – PH35 - Type 2 diabetes prevention: population and community-level interventions
- NICE (Public Health) Guideline – NG16 - Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset
- NICE Guideline NG 33 – Tuberculosis
- NICE (Public Health) Guideline – NG34 - Sunlight exposure: risks and benefits
- NICE (Public Health) Guideline – NG13 - Workplace health: management practices
- NICE Technology Appraisal TA 98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
- NICE Clinical Guideline NG45 - Routine preoperative tests for elective surgery
- NICE Technology Appraisal TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
- NICE Technology Appraisal TA388 - Sacubitril valsartan for treating heart failure with systolic dysfunction
- NICE Technology Appraisal TA 386 - Ruxolitinib for treating related splenomegaly or symptoms in adults with myelofibrosis
- NICE Technology Appraisal NICE TA 23 - Temozolomide for the treatment of recurrent malignant glioma (brain cancer)
- NICE (Clinical) Guideline CG32 - Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
- NICE Clinical Guideline CG97 - Lower urinary tract symptoms in men: assessment and management – Addendum
- NICE (Public Health) Guideline – PH38 - Type 2 diabetes: prevention in people at high risk
- NICE Technology Appraisal TA 391 - Cabazitaxel for hormone relapsed metastatic prostate cancer treated with docetaxel (review of TA255)
- NICE (Public Health) Guideline – NG30 - Oral health promotion: general dental practice
- NICE (Public Health) Guideline – PH55 - Oral health: local authorities and partners
- NICE Technology Appraisal TA 390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- National Statistics – proposed changes to DHSSPS statistical publications
- Standards for Supported Lodgings for Young Adults (aged 16-21) in Northern Ireland
- The remodelling of the administrative structures of the Health and Social Care system
- Consideration Stage amendments to the Mental Capacity Bill